文献速递产科母胎医学

早期标准化治疗危重血压升高与子痫和严重孕产妇发病率降低相关

Early standardized treatment of critical blood pressure elevations is associated with a reduction in eclampsia and severe maternal morbidity.
PubMed 文献 · Am J Obstet Gynecol · 2017-01-30

这项前瞻性质量改进项目纳入23家医院,对持续收缩压≥160 mmHg和/或舒张压≥110 mmHg者推荐静脉降压药与硫酸镁治疗。18个月内69449次分娩中1520例符合持续危重血压升高,依从性从50.5%升至>90%(P<.001),子痫发生率下降42.6%,严重孕产妇发病率下降16.7%(P<.01)。

要点

  • 持续收缩压≥160 mmHg和/或舒张压≥110 mmHg时推荐静脉降压药与硫酸镁治疗。
  • 无监测时对州和国家治疗指南的依从性低(初始50.5%)。
  • 依从性可在较短时间内升至>90%,子痫发生率下降42.6%。

核心结论

  • 早期对经验证的持续危重孕产妇血压使用静脉降压药和硫酸镁,使子痫发生率和严重孕产妇发病率显著降低。
  • 子痫发生率的下降只能部分归因于硫酸镁使用的增加,提示降压药与硫酸镁联合治疗可能具有相加或协同效应。

研究设计与样本

  • 前瞻性质量改进项目,共23家医院参与。
  • 2015年1月至6月收集基线数据,2015年7月至2016年6月持续监测依从性。
  • 研究期间18个月内共有69449次分娩,其中2034例符合危重血压升高、子痫前期或伴严重特征的慢性高血压并发子痫前期标准,该组中1520例存在持续危重血压升高。

主要发现

  • 初始治疗推荐依从性为50.5%,2016年4月后升至>90%(P<.001)。
  • 静脉降压药使用依从性从基线57.1%升至监测最后6个月的90.3%,提高33.2%(P<.01)。
  • 硫酸镁使用依从性从基线85.4%升至96.2%,提高10.8%(P<.01)。
  • 子痫发生率从1.15±0.15/1000次分娩降至0.62±0.09/1000次分娩,下降42.6%。
  • 严重孕产妇发病率从2.4±0.10%降至2.0±0.15%,下降16.7%(P<.01)。

关键数值与推荐

  • 治疗推荐包括:持续收缩压≥160 mmHg和/或舒张压≥110 mmHg时使用静脉血压药物和硫酸镁。
  • 依从性指标为三项全部达标或全不达标:静脉降压药使用、硫酸镁使用、及时获得产后随访预约;缺少任一项即判定为不依从。

临床怎么用

  • 本项目采用标准化方案治疗危重血压升高,包括静脉降压药和硫酸镁,并监测依从性。
  • 依从性指标为三项全部达标或全不达标,缺少任一项即判定为不依从。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypertensive disorders of pregnancy result in significant maternal morbidity and mortality. State and national guidelines have been proposed to increase treatment of patients with hypertensive emergencies or critically elevated blood pressures. There are limited data available to assess the impact of these recommendations on maternal morbidity. OBJECTIVE: The purpose of this prospective quality improvement project was to determine if maternal morbidity would be improved using a standardized approach for treatment of critically elevated blood pressures. STUDY DESIGN: In all, 23 hospitals participated in this project. Treatment recommendations included the use of an intravenous blood pressure medication and magnesium sulfate when there was a sustained blood pressure of ≥160 mm Hg systolic and/or ≥110 mm Hg diastolic. Compliance with the metric recommendations was monitored based on the number of patients treated with an intravenous blood pressure medication, use of magnesium sulfate, and if they received a timely postpartum follow-up appointment. The metric was scored as all or none; missing any of the 3 metric components was considered noncompliant. From January through June 2015 baseline data were collected and hospitals were made aware that ongoing monitoring of compliance would begin in July 2015 through June 2016. The primary outcomes were composite metric compliance, the incidence of eclampsia per 1000 births, and severe maternal morbidity. RESULTS: During the 18 months of this study there were 69,449 births. Within this population, 2034 met criteria for a critically elevated blood pressure, preeclampsia, or superimposed preeclampsia with severe features. Of this group, 1520 had a sustained critical blood elevation. Initial compliance with treatment recommendations was low (50.5%) and increased to >90% after April 2016 (P < .001). Compliance with utilization of intravenous blood pressure medication increased by 33.2%, from a baseline of 57.1-90.3% (P < .01) during the last 6 months of monitoring. Compliance with utilization of magnesium sulfate increased by 10.8%, from a baseline of 85.4-96.2% (P < .01). The incidence of eclampsia declined by 42.6% (1.15 ± 0.15/1000 to 0.62 ± 0.09/1000 births). Severe maternal morbidity decreased by 16.7% from 2.4 ± 0.10% to 2.0 ± 0.15% (P < .01). CONCLUSION: We noted 3 important findings: (1) compliance with state and national treatment guidelines is low without monitoring; (2) high levels of compliance can be achieved in a relatively short period of time; and (3) early intervention with intravenous blood pressure medication and magnesium sulfate for verified sustained critical maternal blood pressures resulted in a significant reduction in the rate of eclampsia and severe maternal morbidity. The reduction in the rate of eclampsia could only partially be attributed to the increase in the use of magnesium sulfate, suggesting an additive or synergistic effect of the combined treatment of an antihypertensive medication and magnesium sulfate on the rate of eclampsia and severe maternal morbidity.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Shields LE, Wiesner S, Klein C, et al. Early standardized treatment of critical blood pressure elevations is associated with a reduction in eclampsia and severe maternal morbidity. Am J Obstet Gynecol. 2017. PMID: 28153655. doi:10.1016/j.ajog.2017.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。